InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Price Performance

NYSE NSPR opened at $2.50 on Thursday. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.77. The company has a market capitalization of $62.33 million, a PE ratio of -3.29 and a beta of 0.91. The company has a fifty day moving average of $2.73 and a 200 day moving average of $2.55.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same period last year, the firm earned ($0.24) EPS. Research analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. lifted its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,513,641 shares of the company’s stock after acquiring an additional 1,827,579 shares during the period. InspireMD accounts for 4.6% of Rosalind Advisors Inc.’s holdings, making the stock its 8th largest position. Rosalind Advisors Inc. owned about 10.08% of InspireMD worth $6,272,000 at the end of the most recent quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.